CURIS INC
Biotech developing innovative cancer therapeutics for hematologic malignancies.
CRIS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US2312693094
- LEI:
- Country:
- United States of America
- Address:
- 128 SPRING STREET, 2421 LEXINGTON
- Website:
- https://www.curis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, with an emphasis on immuno-oncology and precision oncology. The company's lead clinical candidate is emavusertib, an orally available, small molecule IRAK4 inhibitor being developed for hematologic malignancies such as leukemia and lymphoma. Its pipeline also includes other drug candidates targeting various cancer pathways, including HDAC/PI3K and immune checkpoints. Curis previously developed Erivedge, a treatment for basal cell carcinoma that is now licensed to a third party.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CURIS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CURIS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CURIS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
